Evidence map›Paper›PMID 32527042›Full record

ArticleInternational journal of molecular sciences2020

Genomic Biomarkers of Survival in Patients with Adenocarcinoma of the Uterine Cervix Receiving Chemoradiotherapy.

Ying-Chun Lin, Yu-Chia Chen, Rui-Yun Chen, Yi-Xuan Huang, Siang-Jyun Tu, Ji-An Liang, Yao-Ching Hung, Lian-Shung Yeh, Wei-Chun Chang, Wu-Chou Lin and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Ying-Chun LinDepartment of Radiation Oncology, China Medical University Hospital, Taichung 404332, Taiwan.
Yu-Chia ChenCenter for Precision Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Rui-Yun ChenDepartment of Pathology, China Medical University Hospital, Taichung 404, Taiwan.
Yi-Xuan HuangDepartment of Laboratory Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Siang-Jyun TuDepartment of Laboratory Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Ji-An LiangDepartment of Radiation Oncology, China Medical University Hospital, Taichung 404332, Taiwan.
Yao-Ching HungGraduate Institute of Clinical Medical Science, School of Medicine, College of Medicine, China Medical University, Taichung 404, Taiwan.
Lian-Shung YehGraduate Institute of Clinical Medical Science, School of Medicine, College of Medicine, China Medical University, Taichung 404, Taiwan.
Wei-Chun ChangGraduate Institute of Clinical Medical Science, School of Medicine, College of Medicine, China Medical University, Taichung 404, Taiwan.
Wu-Chou LinDepartment of Obstetrics and Gynecology, China Medical University Hospital, Taichung 404, Taiwan.
Yin-Yi ChangDepartment of Obstetrics and Gynecology, China Medical University Hospital, Taichung 404, Taiwan.
Shang-Wen ChenDepartment of Radiation Oncology, China Medical University Hospital, Taichung 404332, Taiwan.
Jan-Gowth ChangCenter for Precision Medicine, China Medical University Hospital, Taichung 404, Taiwan.
China Medical University · TW

Funding

China Medical University Hospital DMR-109-053undefined <span style="color:gray;font-size:10px;">undefined</span> MOST107-2314-B-038-028
6 · The paper itself

Abstract

This study investigated the prognostic effects of genomic biomarkers for predicting chemoradiotherapy (CRT)-based treatment outcomes in patients with adenocarcinoma (AC) of the uterine cervix. In all, 21 patients receiving definitive CRT were included. In accordance with the International Federation of Gynecology and Obstetrics (FIGO) staging system, 5, 8, and 8 patients were classified as having stage IB3, II, and III disease, respectively. Pretreatment biomarkers were analyzed using tissue microarrays from biopsy specimens. Genomic alterations were examined by next-generation sequencing (NGS). The outcome endpoints were disease-free survival (DFS), distant metastasis-free survival (DMFS), and local relapse-free survival (LRFS). A Cox regression model was used to examine the prognostic effects of the biomarkers and clinical parameters. The presence of myeloid cell leukemia-1 (

Indexed as

AdenocarcinomaAdultAgedBiomarkers, TumorChemoradiotherapyDisease-Free SurvivalFemaleHigh-Throughput Nucleotide SequencingHumansMiddle AgedMyeloid Cell Leukemia Sequence 1 ProteinNeoplasm Recurrence, LocalPrognosisUterine Cervical NeoplasmsBiomarkers, TumorMCL1 protein, humanMyeloid Cell Leukemia Sequence 1 Proteincervical adenocarcinomachemoradiotherapygenomic alterationmyeloid cell leukemia-1next-generation sequencing

Identifiers

PMID32527042
PMCPMC7312424
OpenAlexW3035492583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.